Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan

Authors not listed

Hoffmann-La Roche · 2007

Abstract

This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer. Patients will be randomized to receive either Tarceva (150 mg po daily) or vinorelbine (60 mg/m2 on days 1 and 8 of cycle 1 and 80 mg/m2 for the other 21 days cycles). The anticipated time on study treatment is until disease progression.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-03 MST

Cite this

APA
Anonymous. (2007). A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan. <em>Hoffmann-La Roche</em>. https://clinicaltrials.gov/study/NCT01196078
Vancouver
Anonymous. A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan. Hoffmann-La Roche. 2007.
BibTeX
@misc{anon2007APhase, title = {A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan}, author = {Anonymous}, journal = {Hoffmann-La Roche}, year = {2007}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings